Skip to content
Nadolol
Corgard, Corzide (nadolol) is a small molecule pharmaceutical. Nadolol was first approved as Corgard on 1982-01-01. It is used to treat angina pectoris, heart failure, hypertension, and myocardial infarction in the USA. The pharmaceutical is active against beta-2 adrenergic receptor and beta-1 adrenergic receptor. In addition, it is known to target beta-3 adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Corgard (generic drugs available since 1993-10-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bendroflumethiazide
+
Nadolol
Tradename
Company
Number
Date
Products
CORZIDEKing PharmaceuticalsN-018647 DISCN1983-05-25
2 products, RLD
Hide discontinued
Nadolol
Tradename
Company
Number
Date
Products
CORGARDUS WorldMedsN-018063 RX1982-01-01
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
corgardNew Drug Application2022-02-16
nadololANDA2023-06-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
angina pectorisEFO_0003913D000787I20
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
myocardial infarctionEFO_0000612D009203I21
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AA: Beta blocking agents, non-selective
— C07AA12: Nadolol
— C07B: Beta blocking agents and thiazides
— C07BA: Beta blocking agents, non-selective, and thiazides
— C07BA12: Nadolol and thiazides
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNADOLOL
INNnadolol
Description
Nadolol, sold under the brand name Corgard among others, is a medication used to treat high blood pressure, heart pain, atrial fibrillation, and some inherited arrhythmic syndromes. It has also been used to prevent migraine headaches and complications of cirrhosis. It is taken orally.
Classification
Small molecule
Drug classanalgesics (mixed opiate receptor agonists/antagonists); beta-blockers (propranolol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
Identifiers
PDB—
CAS-ID42200-33-9
RxCUI7226
ChEMBL IDCHEMBL649
ChEBI ID—
PubChem CID39147
DrugBankDB01203
UNII IDFEN504330V (ChemIDplus, GSRS)
Target
Agency Approved
ADRB2
ADRB2
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
154
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Q9UMZ5
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Alternate
ADRB3
ADRB3
Organism
Homo sapiens
Gene name
ADRB3
Gene synonyms
ADRB3R, B3AR
NCBI Gene ID
155
Protein name
beta-3 adrenergic receptor
Protein synonyms
adrenergic, beta-3-, receptor, Beta-3 adrenoceptor, Beta-3 adrenoreceptor
Uniprot ID
Q4JFT4
Mouse ortholog
Adrb3 (11556)
beta-3 adrenergic receptor (Q9QZ98)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,447 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2 adverse events reported
View more details